Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bruker Awarded Fourth PeakForce Tapping Patent

Published: Thursday, July 24, 2014
Last Updated: Thursday, July 24, 2014
Bookmark and Share
AFM mode uniquely combines highest resolution imaging and material property mapping.

Bruker has announced that it has recently been awarded its fourth patent for PeakForce Tapping®, its proprietary atomic force microscopy mode that uniquely provides a combination of the highest resolution AFM imaging with the most quantitative property mapping data possible. The patent is issued for the PeakForce Tapping’s specific method of achieving piconewton level, direct force control.

PeakForce Tapping comprises a series of patents that started with the novel concept of high-speed mechanical property mapping (US patent 7,658,097) and evolved into a family of unique AFM modes that include ScanAsyst® (US patent 8,650,660), PeakForce QNM® (US patent 8,646,109) and the recently issued PeakForce Tapping control (US patent 8,739,309).

This series of patented offerings have enabled researchers of all AFM experience levels to perform atomic force microscopy imaging with unprecedented precision in force control and access physical properties information at the nanometer scale for broader category of materials. Additionally, PeakForce Tapping has been extended to electrical AFM modes, such as PeakForce TUNA™ and PeakForce KPFM™.

“As PeakForce Tapping maps the surface, we use feedback to keep the peak interaction force constant, down to tens of piconewtons, in both air and fluid. Because of this simplicity and direct force control, we can preserve the tip as sharp as a few nanometers, which gives us consistent high resolution, including resolving individual atoms,” explained Dr. Chanmin Su, PeakForce Tapping co-inventor and Senior Director of Technology of Bruker’s AFM Business. “Direct force control at pN level and ability to maintain performance for broad range of samples enable users to acquire high-quality images easily, even on complicated samples as multi-component polymers, biomolecules and cells. At the same time the technology provides rich, high-resolution quantitative nanomechanical and nano-electrical data.”

“This latest patent for PeakForce Tapping adds to the rapidly growing list of PeakForce Tapping technology advances that are empowering our customers’ AFM work in both materials and life sciences research,” added David V. Rossi, Executive Vice President and General Manager of Bruker's AFM Business. “With its ability to achieve the highest resolution imaging while providing quantitative property mapping on whatever you measure, PeakForce Tapping continues to fulfill the full promise of how AFMs can enable the highest level of scientific research. This is supported by the fact that PeakForce Tapping has led to over 700 peer-reviewed publications since its inception. We are very pleased that we have been able to bring this unique technology to the scientific community while also removing some of the traditional barriers associated with atomic force microscopy.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Bruker and SAT Announce Joint Publication
Publication of study on SISCAPA-MALDI-TOF mass spectrometry for biomarker validation and clinical research.
Monday, April 23, 2012
Bruker Celebrates Double Award Win at Pittcon 2012
The new GC-MS platform from Bruker Chemical and Applied Markets (CAM) Division – SCION TQ™ – picked up two prestigious awards at last week’s Pittcon in Orlando, Florida.
Tuesday, March 20, 2012
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Ribosome Recycling as a Drug Target
Researchers explain mechanism that recycles bacterial ribosomes stalled on messenger RNAs that lack termination codons.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
Cancer Signaling Pathway Illuminating Way To Therapy
Researchers refine a pro-growth signalling pathway, common to cancers, that can kill cancer cells while leaving healthy cells unharmed.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!